Key result
Higher LDL-C variability linked to ~2% greater risk of major cardiovascular events.
Why the study?
Does increased visit-to-visit LDL-C variability predict adverse cardiovascular outcomes across different lipid-lowering strategies?
Observational (n=6,800)
Does increased visit-to-visit LDL-C variability predict adverse cardiovascular outcomes across different lipid-lowering strategies?
Answers are grounded in this paper and cite their sources.
Increased visit-to-visit LDL-C variability is independently associated with a higher risk of adverse cardiovascular outcomes, and this variability is higher with a treat-to-target strategy compared to high-intensity statin therapy.
Purpose:We aimed to compare the visit-to-visit variability in low-density lipoprotein cholesterol (LDL-C) according to different lipid-lowering strategies and evaluate its prognostic implications using data from previous trials. Materials and Methods:We analyzed two randomized clinical trials: the RACING trial and the LODESTAR trial.LDL-C variability was evaluated using standard deviation (SD), coefficient of variation, and variation independent of mean.The primary endpoint was a composite of death, myocardial infarction, stroke, or coronary revascularization.Results: Among the 6800 patients included, when compared with patients randomized to high-intensity statins, LDL-C variability was similar in the group randomized to moderate-intensity statin plus ezetimibe combination, but it was higher in those randomized to treat-to-target strategy.The variability in LDL-C (by SD) was a predictor of primary endpoint even after adjustment for lipidlowering strategy and mean LDL-C (hazard ratio 1.024; 95% confidence interval 1.014 to 1.035; p<0.001).Every 1-SD increase in LDL-C variability (SD) was also independently associated with higher risk of myocardial infarction by 2.1%, stroke by 3.5%, and coronary revascularization by 2.7%.Conclusion: Compared to high-intensity statin therapy, LDL-C variability was not increased with the moderate-intensity statin plus ezetimibe combination therapy; however, it was increased in the treat-to-target strategy.Even among those treated with moderate-or high-intensity statins or statins with a target LDL-C levels of 50-70 mg/dL, increased LDL-C variability was associated with higher risk of adverse cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) conducted an observational in Patients on lipid-lowering therapy (n=6,800). LDL-C variability was evaluated on composite of death, myocardial infarction, stroke, or coronary revascularization (HR 1.024, 95% CI 1.014-1.035, p=<0.001). Increased LDL-C variability was independently associated with a higher risk of death, myocardial infarction, stroke, or coronary revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: